Ovid Therapeutics Q2 2021 Earnings Report
Key Takeaways
Ovid Therapeutics reported its Q2 2021 financial results, highlighting a strong cash position of $212.2 million and recent appointments to the company's leadership team aimed at advancing neuroscience programs. The company's operating expenses were $14.3 million, but non-GAAP adjusted operating expenses were $10.0 million, within the company's guidance.
Ended Q2 2021 with cash and cash equivalents of $212.2 million.
Appointed experts with neuroscience development and investment acumen to the board and advisory team.
Executive appointments deepen management capability of senior team.
Two, pivotal Phase 3 clinical studies of soticlestat for Dravet syndrome and Lennox-Gastaut syndrome, operated and funded by Takeda, are expected to commence in 2021.
Ovid Therapeutics
Ovid Therapeutics
Forward Guidance
Ovid expects operating expenses (less non-recurring expenses and non-cash expenses) to remain in the $8.0 - $10.0 million range for the remaining quarters of 2021.